Cargando…
Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma
Background: Due to resistance to conventional therapy, a blood–brain barrier that results in poor drug delivery, and a high potential for metastasis, glioblastoma (GBM) presents a great medical challenge. Since the repertoire of the possible therapies is very limited, novel therapeutic strategies re...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406037/ https://www.ncbi.nlm.nih.gov/pubmed/36009010 http://dx.doi.org/10.3390/biom12081116 |
_version_ | 1784774025634906112 |
---|---|
author | Sowińska, Marta Szeliga, Monika Morawiak, Maja Zabłocka, Barbara Urbanczyk-Lipkowska, Zofia |
author_facet | Sowińska, Marta Szeliga, Monika Morawiak, Maja Zabłocka, Barbara Urbanczyk-Lipkowska, Zofia |
author_sort | Sowińska, Marta |
collection | PubMed |
description | Background: Due to resistance to conventional therapy, a blood–brain barrier that results in poor drug delivery, and a high potential for metastasis, glioblastoma (GBM) presents a great medical challenge. Since the repertoire of the possible therapies is very limited, novel therapeutic strategies require new drugs as well as new approaches. The multiple roles played by L-tryptophan (Trp) in tumorigenesis of GBM and the previously found antiproliferative properties of Trp-bearing dendrimers against this malignancy prompted us to design novel polyfunctional peptide-based dendrimers covalently attached to N(1)-alkyl tryptophan (Trp) residues. Their antiproliferative properties against GBM and normal human astrocytes (NHA) and their antioxidant potential were tested. Methods: Two groups of amphiphilic peptide dendrimers terminated with N(1)-butyl and N(1)-aminopentane tryptophan were designed. The influence of dendrimers on viability of NHA and human GBM cell lines, displaying different genetic backgrounds and tumorigenic potentials, was determined by the MTT test. The influence of compounds on the clonogenic potential of GBM cells was assessed by colony-formation assay. Dendrimers were tested for radical scavenging potency as well as redox capability (DPPH, ABTS, and FRAP models). Results: Several peptide dendrimers functionalized with N(1)-alkyl-tryptophan at 5 µM concentration exhibited high selectivity towards GBM cells retaining 85–95% viable NHA cells while killing cancer cells. In both the MTT and colony-formation assays, compounds 21 (functionalized with N(1)-butyl-Trp and (+)8 charged) and 25 (functionalized with N(1)-aminopentane-Trp and (+)12 charged) showed the most promise for their development into anticancer drugs. According to ABTS, DPPH, and FRAP antioxidant tests, dendrimers functionalized with N(1)-alkylated Trp expressed higher ROS-scavenging capacity (ABTS and DPPH) than those with unsubstituted Trp. Conclusions: Peptide dendrimers functionalized with N(1)-alkyl-tryptophan showed varying toxicity to NHA, while all were toxic to GBM cells. Based on their activity towards inhibition of GBM viability and relatively mild effect on NHA cells the most advantageous were derivatives 21 and 25 with the respective di-dodecyl and dodecyl residue located at the C-terminus. As expected, peptide dendrimers functionalized with N(1)-alkyl-tryptophan expressed higher scavenging potency against ROS than dendrimers with unsubstituted tryptophan. |
format | Online Article Text |
id | pubmed-9406037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94060372022-08-26 Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma Sowińska, Marta Szeliga, Monika Morawiak, Maja Zabłocka, Barbara Urbanczyk-Lipkowska, Zofia Biomolecules Article Background: Due to resistance to conventional therapy, a blood–brain barrier that results in poor drug delivery, and a high potential for metastasis, glioblastoma (GBM) presents a great medical challenge. Since the repertoire of the possible therapies is very limited, novel therapeutic strategies require new drugs as well as new approaches. The multiple roles played by L-tryptophan (Trp) in tumorigenesis of GBM and the previously found antiproliferative properties of Trp-bearing dendrimers against this malignancy prompted us to design novel polyfunctional peptide-based dendrimers covalently attached to N(1)-alkyl tryptophan (Trp) residues. Their antiproliferative properties against GBM and normal human astrocytes (NHA) and their antioxidant potential were tested. Methods: Two groups of amphiphilic peptide dendrimers terminated with N(1)-butyl and N(1)-aminopentane tryptophan were designed. The influence of dendrimers on viability of NHA and human GBM cell lines, displaying different genetic backgrounds and tumorigenic potentials, was determined by the MTT test. The influence of compounds on the clonogenic potential of GBM cells was assessed by colony-formation assay. Dendrimers were tested for radical scavenging potency as well as redox capability (DPPH, ABTS, and FRAP models). Results: Several peptide dendrimers functionalized with N(1)-alkyl-tryptophan at 5 µM concentration exhibited high selectivity towards GBM cells retaining 85–95% viable NHA cells while killing cancer cells. In both the MTT and colony-formation assays, compounds 21 (functionalized with N(1)-butyl-Trp and (+)8 charged) and 25 (functionalized with N(1)-aminopentane-Trp and (+)12 charged) showed the most promise for their development into anticancer drugs. According to ABTS, DPPH, and FRAP antioxidant tests, dendrimers functionalized with N(1)-alkylated Trp expressed higher ROS-scavenging capacity (ABTS and DPPH) than those with unsubstituted Trp. Conclusions: Peptide dendrimers functionalized with N(1)-alkyl-tryptophan showed varying toxicity to NHA, while all were toxic to GBM cells. Based on their activity towards inhibition of GBM viability and relatively mild effect on NHA cells the most advantageous were derivatives 21 and 25 with the respective di-dodecyl and dodecyl residue located at the C-terminus. As expected, peptide dendrimers functionalized with N(1)-alkyl-tryptophan expressed higher scavenging potency against ROS than dendrimers with unsubstituted tryptophan. MDPI 2022-08-13 /pmc/articles/PMC9406037/ /pubmed/36009010 http://dx.doi.org/10.3390/biom12081116 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sowińska, Marta Szeliga, Monika Morawiak, Maja Zabłocka, Barbara Urbanczyk-Lipkowska, Zofia Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma |
title | Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma |
title_full | Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma |
title_fullStr | Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma |
title_full_unstemmed | Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma |
title_short | Design, Synthesis and Activity of New N(1)-Alkyl Tryptophan Functionalized Dendrimeric Peptides against Glioblastoma |
title_sort | design, synthesis and activity of new n(1)-alkyl tryptophan functionalized dendrimeric peptides against glioblastoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406037/ https://www.ncbi.nlm.nih.gov/pubmed/36009010 http://dx.doi.org/10.3390/biom12081116 |
work_keys_str_mv | AT sowinskamarta designsynthesisandactivityofnewn1alkyltryptophanfunctionalizeddendrimericpeptidesagainstglioblastoma AT szeligamonika designsynthesisandactivityofnewn1alkyltryptophanfunctionalizeddendrimericpeptidesagainstglioblastoma AT morawiakmaja designsynthesisandactivityofnewn1alkyltryptophanfunctionalizeddendrimericpeptidesagainstglioblastoma AT zabłockabarbara designsynthesisandactivityofnewn1alkyltryptophanfunctionalizeddendrimericpeptidesagainstglioblastoma AT urbanczyklipkowskazofia designsynthesisandactivityofnewn1alkyltryptophanfunctionalizeddendrimericpeptidesagainstglioblastoma |